You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

high risk smoldering myeloma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

Not yet recruiting
  • Multiple Myeloma
  • Miami, Florida
    University of Miami
Oct 20, 2023

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Ciltacabtagene Autoleucel
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 2, 2023

High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,

Recruiting
  • High-risk Smoldering Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Aug 11, 2022

Smoldering Multiple Myeloma Trial (Selinexor)

Not yet recruiting
  • Smoldering Multiple Myeloma
  • (no location specified)
Oct 27, 2022

Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

Not yet recruiting
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)
  • (no location specified)
Nov 17, 2023

Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

Not yet recruiting
  • Smoldering Multiple Myeloma (SMM)
  • (no location specified)
Jul 13, 2023

Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Smoldering Multiple Myeloma Trial in Boston (Nivolumab, Lenalidomide, Dexamethasone)

Suspended
  • Smoldering Multiple Myeloma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 4, 2022

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Oslo (TG01)

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • TG01
  • Oslo, Norway
    Oslo Myeloma Center
May 2, 2023

Multiple Myeloma, High Risk Smoldering Multiple Myeloma Trial in United States (Ixazomib (MLN9708), Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • High Risk Smoldering Multiple Myeloma
  • Basking Ridge, New Jersey
  • +5 more
Nov 15, 2022

Myeloma Trial in Houston (Belantamab mafodotin)

Recruiting
  • Myeloma
  • Belantamab mafodotin
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Smoldering Plasma Cell Myeloma Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)

Active, not recruiting
Has Results
  • Smoldering Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Mar 23, 2022

Smoldering Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Daratumumab)

Active, not recruiting
  • Smoldering Multiple Myeloma
  • Tampa, Florida
  • +9 more
Jul 8, 2022

High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)

Recruiting
  • High-risk Smoldering Multiple Myeloma
  • Multiple Myeloma
  • Boston, Massachusetts
  • +1 more
Oct 18, 2021

Monoclonal Gammopathy, Smoldering Multiple Myeloma Trial in United States (Daratumumab)

Active, not recruiting
  • Monoclonal Gammopathy
  • Smoldering Multiple Myeloma
  • Monterey, California
  • +5 more
Nov 1, 2021

Smoldering Myeloma, Smoldering Multiple Myeloma Trial in United States (Elotuzumab, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Smoldering Myeloma
  • Smoldering Multiple Myeloma
  • Denver, Colorado
  • +8 more
Nov 1, 2021

Smouldering Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Lenalidomide)

Recruiting
  • Smouldering Myeloma
  • Brno, Czechia
  • +15 more
Mar 22, 2022

Multiple Myeloma Trial in Austria, Germany, Israel (Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA], Placebo 1.7 ml

Active, not recruiting
  • Multiple Myeloma
  • Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
  • Placebo 1.7 ml Subcutaneous Solution
  • Graz, Austria
  • +9 more
Aug 24, 2022

High Risk Smoldering Multiple Myeloma Trial in New York (Ibrutinib)

Terminated
Has Results
  • High Risk Smoldering Multiple Myeloma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Nov 18, 2020

Smoldering Multiple Myeloma Trial in Spain (carfilzomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Smoldering Multiple Myeloma
  • Barcelona, Spain
  • +15 more
Feb 15, 2021

Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM) Trial in Rochester (Curcumin plus Piperine)

Recruiting
  • Prostate Cancer
  • +3 more
  • Curcumin plus Piperine
  • Rochester, New York
    University of Rochester
Jun 17, 2022

Smoldering Multiple Myeloma Trial in France, Germany, United States (BHQ880)

Completed
  • Smoldering Multiple Myeloma
  • Fayetteville, Arkansas
  • +12 more
Dec 11, 2020

Healthy Trial (blood sampling)

Not yet recruiting
  • Healthy
  • blood sampling
  • (no location specified)
Apr 20, 2023

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +2 more
  • Wuhan, Hubei, China
    Institute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023